TokenPost·
Arrowhead Targets U.S. REDEMPLO Launch for Q2 2027, Subject to FDA Approval
The company reiterated a $3 billion to $4 billion U.S. sales opportunity and said it is too early to provide sales guidance.
More news
- TokenPostUltra (UOS) Falls 9.13% in 15 Minutes as Daily Loss Hits 28.16%
- TokenPostPoste Italiane’s Management-View Revenue Rises 5.4% in Nine Months
- TokenPostWienerberger Q3 Revenue Rises About 8% as Operating EBITDA Falls
- TokenPostBitcoin Liquidation Map Shows $276 Million in Long-Side Intensity Below $67,000
- TokenPostHireQuest Posts High-Teens System-Wide Sales Growth in Early Q4
- TokenPostUniswap Falls 5.40% in Four Hours to $5.76 on Binance Spot